ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2018
[Clinical Evaluation of A New Pathological Classification for Non-small Cell Lung Cancer Based on Histogenesis of Bronchial Tree].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- [Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue in part to remarkable advances over the past decade in our understanding of lung cancer, there is a pressing need for a revised classification. The aim of this study was to explore and verify the clinical significance of a new molecular classification of non-small cell lung cancer (NSCLC) on the basis of anatomic site of bronchial tree.
methodsDouble-immunohistochemistry were performed in 105 tumor samples paring with normal lung tissue from non-small cell lung cancer patients by using monoclonal antibody of P63/NapsinA and TTF-1/CK7. By comprehensively analyzing the express profiles of tumors and normal lung tissues, histological characteristics we proposed a brand new pathological classification based on histogenesis for NSCLC and divided them as: bronchiole epithelial cell carcinoma, bronchiole-alveolar cell carcinoma, alveolar cell carcinoma and secretory adenocarcinoma. And to analyze the relationship between this classification and epidermal growth factor receptor (EGFR) mutation and ognosis.
resultsFurther investigation revealed that our new classification showed strong relevancy with EGFR mutations and effective indicators for prognosis.
conclusionsThe classification system for NSCLC proposed by our research group is convenient for pathological diagnosis and valuable in clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.